XILIO THERAPEUTICS, INC.

Consensus Xilio Therapeutics, Inc.

Stocks

XLO

US98422T2096

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-14 EDT			5-day change	1st Jan Change
8.930 ^USD	0.00%		-0.78%	-0.37%

08-12	Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index	CI

Evolution of the Average Target: Xilio Therapeutics, Inc.

Evolution of the Target Price: Xilio Therapeutics, Inc.

Changes in Analyst Recommendations: Xilio Therapeutics, Inc.

73c3c8845eb91.TNhUTNPiGODjltN_8DQecopWt1DukYkgmJY9Fz1DCxI.K6wSGIeIWpaB4ZUlnkwvB71n9COPqeFp6MFqc0QXcSI76mAGlNEg0ITc4w~a9af5390f4de8f8de7e09c370f6629f4

Analysts' recommendations: Xilio Therapeutics, Inc.

25-08-06	Leerink Partners Initiates Xilio Therapeutics at Outperform With $2 Price Target	MT
23-01-27	Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating	MT
22-12-21	Chardan Initiates Xilio Therapeutics With Buy Rating, $7 Price Target	MT
22-11-10	Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating	MT
22-08-10	Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $20 From $32, Reiterates Overweight Rating	MT
22-01-10	HC Wainwright Starts Xilio Therapeutics at Buy with $36 Price Target	MT
21-11-16	Guggenheim Starts Xilio Therapeutics at Buy With $40 Price Target	MT
21-11-16	Raymond James Starts Xilio Therapeutics at Outperform With $31 Price Target	MT
21-11-16	Morgan Stanley Starts Xilio Therapeutics at Overweight With $32 Price Target	MT
21-11-16	Cowen Starts Xilio Therapeutics at Outperform	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	XILIO THERAPEUTICS, INC.			-	-	+123.96%
	LONZA GROUP AG					+29.55%
	REVOLUTION MEDICINES, INC.					+23.28%
	IQVIA HOLDINGS INC.					+5.54%
	BEONE MEDICINES AG					+24.9%
	CELLTRION, INC.					+50.52%
	ASCENDIS PHARMA A/S					+19.38%
	MEDPACE HOLDINGS, INC.					-0.97%
	EUROFINS SCIENTIFIC SE					+2.18%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+1.5%
	Average					+27.99%
	Weighted average by Cap.					+21.03%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

8.930USD

Average target price

20.00USD

Spread / Average Target

+123.96%

High Price Target

20.00USD

Spread / Highest target

+123.96%

Low Price Target

20.00USD

Spread / Lowest Target

+123.96%

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
XLO Stock
Consensus Xilio Therapeutics, Inc.

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!